Cooperative research and development agreement

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, November 9, 2023
Cream, Female, FDA, Bacterial vaginosis, Research, Human development, Trial of the century, Cooperative research and development agreement, Vaginal discharge, Food, Hot, Organon, Human services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, G&A, Progesterone, Phase 3, Quarter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Call, Development, NICHD, Webcast, Clinical trial, ID, Tamoxifen, FSAD, Bacteria, Hormone, NIH, Woman, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Patient, Bangladesh Technical Education Board, Pharmaceutical industry, Birth control, Bayer, Conference

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.
  • XACIATO™ provides a new therapeutic option for the millions of women suffering from bacterial vaginosis in the U.S.
  • Financial Highlights for the Quarter ended September 30, 2023
    Cash and cash equivalents: $13.8 million at September 30, 2023.
  • Daré will host a conference call and live webcast today, November 9, 2023, at 4:30 p.m. Eastern Time to review financial results for the quarter ended September 30, 2023 and to provide a company update.

Legacy, the Leading At-Home Sperm Testing and Freezing Company, to Offer Discounted Services for All Military Members and Veterans this Veterans Day

Retrieved on: 
Wednesday, November 8, 2023
Fertility, National Guard, Veterans Health Administration, United States Naval Special Warfare Command, Cooperative research and development agreement, War on terror, Military personnel, Heart, Family, National Guard Forces Command, Sperm, Development, Male, Injury, Partnership, Freezing, Blood, Army, Veterans Day, Hearing, Infertility, Physical fitness, Birth control, Airline, Legacy, Veteran

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Legacy, America's largest at-home male fertility clinic, announced today that it will increase its special offer on sperm testing and freezing services for active duty service members, reservists, members of the National Guard, and Veterans in honor of Veterans Day.

Key Points: 
  • This announcement comes on the heels of a 40% spike in demand for sperm freezing services for military personnel over the past 30 days.
  • To date, over 200 special operators and over 1,000 conventional military personnel have benefitted from Legacy's services.
  • Legacy recently entered into a Cooperative Research and Development Agreement with the Veterans Health Administration to test and cryopreserve sperm for over 1,000 Global War On Terror veterans across the United States.
  • This expanded Veterans Day discount reinforces Legacy's commitment to solve fertility challenges faced by military families.

Verizon Public Sector Teams Up With Dept. of Veterans Affairs to Provide Broadband for Veterans

Retrieved on: 
Tuesday, November 7, 2023
CRADA, Government, Cooperative research and development agreement, NYSE, Verizon Communications, Health, VA Palo Alto Health Care System, Architecture, MD, Network as a service, United States Department of Veterans Affairs, Development, Advertising, VHA, Senior, History of the United States government, Internet, Partnership, Digital divide, VZ, Public sector, LEO, RSS, Mobile phone, Veterans' affairs, Veteran

This groundbreaking project has begun at the VA Palo Alto Health Care System, a network known for delivering next-generation healthcare solutions now for Veterans.

Key Points: 
  • This groundbreaking project has begun at the VA Palo Alto Health Care System, a network known for delivering next-generation healthcare solutions now for Veterans.
  • “Our goal is to provide the best and most advanced healthcare possible for our Veterans,” said Thomas Osborne, MD, Director of NCCHI.
  • Verizon Public Sector also recently equipped VA Palo Alto Health Care System with a full spectrum private 5G network that enables unprecedented pathways to care for its Veterans.
  • “The objective of this collaboration between Verizon Public Sector and the VA is to help bridge the Digital Divide for our nation’s veterans,” said Maggie Hallbach, Senior Vice President, Verizon Public Sector.

GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023

Retrieved on: 
Monday, November 6, 2023
Regulatory T cell, CRADA, Society for Immunotherapy of Cancer, IND, Cooperative research and development agreement, NCI, Immunodeficiency, Biotechnology, Data, Development, SITC, Immunotherapy, Partnership, National Cancer Institute, Annual general meeting, Infection, Tumor microenvironment, Cancer, Patient, Toxicity, Bangladesh Technical Education Board, SAN, Pharmaceutical industry, Vaccine, Oncology, Grifols

SAN CARLOS, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, presented investigational new drug (IND)-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company’s oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • The comprehensive dataset from non-clinical models continues to demonstrate GIGA-564’s potential to improve outcomes for cancer patients through weak checkpoint inhibition of CTLA-4.
  • GIGA-564 depletes intratumoral T regulatory cells (Tregs) within the tumor microenvironment, which enables the tumor-killing activity of cytotoxic T cells.
  • The Phase 1a/1b dose escalation and dose-expansion trial, expected to start in 2024, will evaluate GIGA-564 for the treatment of advanced solid tumors.
  • “We are pleased to present the design of this first-in-human Phase 1 trial for GIGA-564,” said Erica Stone, vice president of Oncology at GigaGen.

Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens

Retrieved on: 
Wednesday, October 25, 2023
CRADA, Ageing, Cooperative research and development agreement, Therapy, Maxwell, United States Army Medical Research and Development Command, Biological warfare, U.S. Army Public Health Center, United States Army Medical Research Institute of Infectious Diseases, Development, USAMRIID, McClure, Infection, Peptide, Vaccine

USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats

Key Points: 
  • Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
  • "As a military veteran, I'm proud to lead a team that tirelessly seeks to fill critical unmet needs for more effective therapeutics against the worst global pathogens."
  • "Our Claromer technology has the potential to replace almost all antibiotics, antifungals and antivirals - and it may help with healthy aging as well," continued McClure.
  • "Signing this CRADA with USAMRIID, the world's preeminent biodefense research organization, is another validation of Maxwell's Claromer technology's potential as an important, disruptive platform technology."

Community Offshore Wind Awarded NYSERDA Offtake Contract to Develop 1.3 GW of Offshore Wind for New York

Retrieved on: 
Tuesday, October 24, 2023
Cooperative research and development agreement, United Nations Ocean Conference, BOEM, NYISO, United Way, Farm, Parent, State, Workforce, Carbon, Wind, General Electric, Fishery, RWE, Bureau of Ocean Energy Management, National Grid, Research, Bureau, NOAA, MWBE, Growth, GE, National Oceanic and Atmospheric Administration, Partnership, New Yorker, Minority business enterprise, Economic development, European Fusion Development Agreement, Climate change, Investment, Today, NYSERDA, Renewable energy, Gulf of Mexico

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- New York State Governor Kathy Hochul today announced that Community Offshore Wind, a joint venture of RWE and National Grid Ventures, was provisionally awarded a 1.3 gigawatt (GW) offtake contract as part of the state's third solicitation for offshore wind.

Key Points: 
  • NEW YORK, Oct. 24, 2023 /PRNewswire/ -- New York State Governor Kathy Hochul today announced that Community Offshore Wind, a joint venture of RWE and National Grid Ventures, was provisionally awarded a 1.3 gigawatt (GW) offtake contract as part of the state's third solicitation for offshore wind.
  • The project awarded by NYSERDA will interconnect into Brooklyn, New York to deliver new offshore wind capacity.
  • Doug Perkins, President and Project Director of Community Offshore Wind: "Community Offshore Wind will propel New York toward its ambitious climate and clean energy goals, while cementing the state as a hub for the continued development of offshore wind in the Northeast.
  • As part of the offtake award from NYSERDA, Community Offshore Wind will play a significant role in strengthening the domestic supply chain.

ACE Green Recycling enters into Lithium-Ion Battery Recycling Research Agreement with National Renewable Energy Laboratory

Retrieved on: 
Wednesday, October 18, 2023
CRADA, Inflation Reduction Act of 2022, Cooperative research and development agreement, Ford, Copper, NREL, Tesla, ACE, Research, Engineering, Development, Environment, LFP, Lithium, National Renewable Energy Laboratory, Recycling, Graphite, DOE, U.S. Department of Defense Strategy for Operating in Cyberspace, Investment, U.S. Department of Energy, Office of Inspector General, Cobalt, Electrode, Electric battery, Nickel

GOLDEN, Colo. , Oct. 18, 2023 /PRNewswire/ -- ACE Green Recycling (ACE) and the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have signed a Cooperative Research and Development Agreement (CRADA) to further develop and optimize ACE's environment friendly and low cost lithium-ion battery recycling technology for recycling of graphite, lithium-iron phosphate (LFP) and other cathode active materials. This collaboration advances DOE's deep commitment and investments in the development of sustainable, cost effective and environment friendly lithium-ion battery recycling in the United States.

Key Points: 
  • GOLDEN, Colo. , Oct. 18, 2023 /PRNewswire/ -- ACE Green Recycling (ACE) and the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have signed a Cooperative Research and Development Agreement (CRADA) to further develop and optimize ACE's environment friendly and low cost lithium-ion battery recycling technology for recycling of graphite, lithium-iron phosphate (LFP) and other cathode active materials.
  • Located in Golden, Colorado, NREL is a DOE national laboratory focused on renewable energy and energy efficiency research and development.
  • As part of this mission, NREL is committed to the development and deployment of key breakthroughs for battery recycling technologies.
  • Under this research agreement, NREL will assist ACE in evaluating commercialization of this process to recycle LFP batteries and to upcycle graphite to battery grade.

ACE Green Recycling enters into Lithium-Ion Battery Recycling Research Agreement with National Renewable Energy Laboratory

Retrieved on: 
Wednesday, October 18, 2023
CRADA, Inflation Reduction Act of 2022, Cooperative research and development agreement, Ford, Copper, NREL, Tesla, ACE, Research, Engineering, Development, Environment, LFP, Lithium, National Renewable Energy Laboratory, Recycling, Graphite, DOE, U.S. Department of Defense Strategy for Operating in Cyberspace, Investment, U.S. Department of Energy, Office of Inspector General, Cobalt, Electrode, Electric battery, Nickel

GOLDEN, Colo., Oct. 18, 2023 /PRNewswire/ -- ACE Green Recycling (ACE) and the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have signed a Cooperative Research and Development Agreement (CRADA) to further develop and optimize ACE's environment friendly and low cost lithium-ion battery recycling technology for recycling of graphite, lithium-iron phosphate (LFP) and other cathode active materials. This collaboration advances DOE's deep commitment and investments in the development of sustainable, cost effective and environment friendly lithium-ion battery recycling in the United States.

Key Points: 
  • GOLDEN, Colo., Oct. 18, 2023 /PRNewswire/ -- ACE Green Recycling (ACE) and the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have signed a Cooperative Research and Development Agreement (CRADA) to further develop and optimize ACE's environment friendly and low cost lithium-ion battery recycling technology for recycling of graphite, lithium-iron phosphate (LFP) and other cathode active materials.
  • Located in Golden, Colorado, NREL is a DOE national laboratory focused on renewable energy and energy efficiency research and development.
  • As part of this mission, NREL is committed to the development and deployment of key breakthroughs for battery recycling technologies.
  • Under this research agreement, NREL will assist ACE in evaluating commercialization of this process to recycle LFP batteries and to upcycle graphite to battery grade.

Volcon ePowersports Announces Cooperative Research and Development Agreement with the United States Army Engineer Research and Development Center

Retrieved on: 
Tuesday, October 10, 2023
Transfer, ERDC, Army, US Army Regulation 25-50, Cooperative research and development agreement, U.S. Department of Defense Strategy for Operating in Cyberspace, Engineering, Private sector, Development, United States Army Corps of Engineers, Engineer Research and Development Center, Corps, EVS, United States Department of Defense, Federal Technology Transfer Act of 1986, U.S. Army Corps of Engineers, Europe District, Energy management, USACE, United States Army Engineer Research and Development Laboratory, CRADA, Construction, Emergency, Research, Gasoline, EV

AUSTIN, Texas, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the United States Army Engineer Research and Development Center, Construction Engineering Research Laboratory (ERDC). Volcon believes this collaboration marks a significant step forward in the development of EV technology for both civilian and military applications.

Key Points: 
  • AUSTIN, Texas, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the United States Army Engineer Research and Development Center, Construction Engineering Research Laboratory (ERDC).
  • Volcon believes this collaboration marks a significant step forward in the development of EV technology for both civilian and military applications.
  • Key objectives of this collaboration include:
    Energy Management: Volcon will provide technical expertise to improve energy management in electric vehicles, including measurement, monitoring, range extension, and export power processes and procedures.
  • Enhanced Tactical Ground Vehicles: Volcon aims to develop enhanced tactical ground vehicle applications to support soldiers and emergency responders in their missions.

Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, MSD, DFS, Cooperative research and development agreement, MRK, NYSE, Development, Rated R, Alliance for Clinical Trials in Oncology, Recurrence, Data monitoring committee, Patient, Merck & Co., NCI, Head, Bladder cancer, Bangladesh Technical Education Board, Observation, Carcinoma, Pharmaceutical industry, Merck

At a pre-specified interim analysis review conducted by an independent Data Monitoring Committee, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in DFS versus observation in these patients after surgery.

Key Points: 
  • At a pre-specified interim analysis review conducted by an independent Data Monitoring Committee, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in DFS versus observation in these patients after surgery.
  • The trial will continue to evaluate its other dual primary endpoint of overall survival (OS).
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Merck provided funding and support through a Cooperative Research and Development Agreement between Merck and NCI.